Q-omics provides the consensus-scored P2RX5-TAX1BP3 profile across patient tissues and cancer cell-line models. P2RX5-TAX1BP3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, P2RX5-TAX1BP3 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, P2RX5-TAX1BP3 RNA expression shows 19,309 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where P2RX5-TAX1BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RX5-TAX1BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RX5-TAX1BP3 survival associations across molecular data types. P2RX5-TAX1BP3 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RX5-TAX1BP3 RNA expression–survival associations across cancer types. High P2RX5-TAX1BP3 expression shows unfavorable associations in ACC and MESO, but favorable associations in PAAD, KIRC, THYM and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for P2RX5-TAX1BP3 RNA expression.
This table summarizes P2RX5-TAX1BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for P2RX5-TAX1BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RX5-TAX1BP3 shows lower tumor expression in THCA, KICH, KIRC, LUAD and BRCA and higher tumor expression in HNSC. The THCA box plot shows higher P2RX5-TAX1BP3 RNA expression in normal versus tumor tissue (log2 FC = −0.713, t-test p < 0.001).
This table shows molecular features associated with P2RX5-TAX1BP3 in patient tissues and cancer cell lines. In patient samples, P2RX5-TAX1BP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RX5-TAX1BP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
